Industry News
Orchestra BioMed and Medtronic move pacemaker-delivered hypertension therapy toward pivotal readout
MODERATO II data presented at Heart Rhythm 2026 shows AVIM Therapy — bioelectronic blood pressure control delivered through a standard dual-chamber pacemaker — produced an 8.1 mmHg net reduction in 24-hour ambulatory systolic BP at six months, with the Medtronic-partnered BACKBEAT pivotal trial now actively enrolling under an FDA-amended protocol.